Hybridoma technology is applied to create a hybrid cell by fusing beta lymphocytes with myeloma cell. By using this technology these hybrid cells obtain power to generate antibodies because of beta lymphocyte genetic components and also gain capability to multiply indefinitely resulting from the attendance of myeloma cells. This hybrid cells generated by using Hybridoma technology that can be cultured in a laboratory or subcultured in a mouse bodily cavity. Monoclonal Antibody are produced from these hybrid cells and this technology is referred as Hybridoma technology.
The production of MAbs by using Hybridoma technology involves following steps:
2. Cell fusion
3. Selection of Hybridomas
5. Cloning and propagation
6. Characterization and storage